

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

PALMER et al.

App. No.:

10/817,312

Confirmation No.:1876

Filing Date:

April 1, 2004

Title:

INHIBITORS OF

PHOSPHODIESTERASES IN

INFERTILITY

Art Unit:

1653

Examiner:

Desai, Anand U.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number

EV 439404832 US

Date of Deposit June 7, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to Mail Stop Petitions, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Michael Collins

yped or printed name of person mailing)

(Signature of person mailing)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, the applicants call to the attention of the examiner the reference listed on the attached Form PTO/SB/08B. An Information Disclosure Statement listing the reference was previously filed on January 19, 2006, but was not considered by the examiner because it lacked a statement as specified in 37 C.F.R. § 1.97(e) and because the submission lacked the fee set forth 10017312 in 37 C.F.R. § 1.17(p). Attorney for applicants submits herewith a copy of the cited reference. It is respectfully requested that this Information Disclosure Statement be entered and the document listed on attached Form PTO/SB/08B be considered by the Examiner and made of record.

Docket No. 05558.0011.NPUS04

Application No. 10/817,312

Filed: April 1, 2004

Page 2

This Information Disclosure Statement is not intended to be an admission that a search

has been made, that other relevant art does not exist, or that any of the information disclosed

herein constitutes art under 35 U.S.C. §102 or §103.

The Information Disclosure Statement is submitted, pursuant to 37 C.F.R. § 1.97 et seq.,

and request that the fee of \$180 be charged to our Deposit Account No. 08-3038. However,

should any further fees be deemed necessary in connection with the filing of this document, the

Commissioner is hereby authorized to deduct any such fees from our Deposit Account No. 08-

3038.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP

Registration No.

Date: June 7, 2006

Howrey Simon Arnold & White, LLP 321 N. Clark Street, Suite 3400

Chicago, Illinois 60610

Tel: (312) 595-1408

Fax: (312) 595-2250

Approved for use through 06/30/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Apt of 1995 no Persons

Substitute for form 1449B/PTO

Sheet

Examiner

Signature

JUN 0 7 2006

INFORMATION DISCLOSUSE STATEMENT BY APPEICANT

(Use as many sheets as necessary)

Application Number 10/817,312

Filing Date April 1, 2004

First Named Inventor Stephen S. Palmer

Art Unit 1653

Examiner Name Desai, Anand U.

Attorney Docket Number 05558.0011.NPUS04

required to respond to a collection of information unless it contains a valid OMR control number.

NON PATENT LITERATURE DOCUMENTS		
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	Improve Uterine Artery Blood Flow and Endometrial Development in Patients Undergoing	
	No. ¹	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Sher, G., et al., "Vaginal Sildenafil (Viagra): A Preliminary Report of a Novel Method to Improve Uterine Artery Blood Flow and Endometrial Development in Patients Undergoing

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.